Wave Life Sciences Ltd. Ordinary Shares
WVE Real Time Price USDRecent trades of WVE by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by WVE's directors and management
Government lobbying spending instances
-
$15,000 Jan 17, 2023 Issue: Health Issues
-
$15,000 Oct 17, 2022 Issue: Health Issues
-
$15,000 Jul 20, 2022 Issue: Health Issues
-
$15,000 Apr 20, 2022 Issue: Health Issues
-
$15,000 Jan 31, 2022 Issue: Health Issues
-
$15,000 Nov 02, 2021 Issue: Health Issues
-
$15,000 Jul 20, 2021 Issue: Health Issues
-
$15,000 Apr 23, 2021 Issue: Health Issues
-
$15,000 Jan 22, 2021 Issue: Health Issues
-
$15,000 Oct 19, 2020 Issue: Health Issues
-
$15,000 Jul 28, 2020 Issue: Health Issues
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Compositions and methods for phosphoramidite and oligonucleotide synthesis Jan. 16, 2024
-
Patent Title: Oligonucleotide compositions and methods thereof Aug. 29, 2023
-
Patent Title: Compounds, compositions and methods for synthesis Aug. 08, 2023
-
Patent Title: Chiral control May. 09, 2023
-
Patent Title: Oligonucleotide compositions and methods thereof Apr. 25, 2023
-
Patent Title: Technologies for oligonucleotide preparation Mar. 21, 2023
-
Patent Title: Oligonucleotide compositions and methods of use thereof Mar. 14, 2023
-
Patent Title: Oligonucleotide compositions and methods of use thereof Mar. 07, 2023
-
Patent Title: Oligonucleotide compositions and methods thereof Mar. 07, 2023
-
Patent Title: Compositions and methods for phosphoramidite and oligonucleotide synthesis Aug. 09, 2022
-
Patent Title: Asymmetric auxiliary group Oct. 05, 2021
-
Patent Title: Oligonucleotides, compositions and methods thereof May. 25, 2021
-
Patent Title: Chiral design Oct. 27, 2020
-
Patent Title: Oligonucleotide compositions and methods thereof Jul. 28, 2020
-
Patent Title: Asymmetric auxiliary group Jun. 30, 2020
-
Patent Title: Chiral control Mar. 17, 2020
-
Patent Title: Oligonucleotide compositions and methods thereof Nov. 19, 2019
-
Patent Title: Oligonucleotide compositions and methods thereof Oct. 22, 2019
-
Patent Title: Chiral auxiliaries Oct. 01, 2019
-
Patent Title: Method for the synthesis of phosphorus atom modified nucleic acids Jun. 25, 2019
-
Patent Title: Nucleic acid prodrugs and methods of use thereof Jun. 04, 2019
-
Patent Title: Methods for the synthesis of functionalized nucleic acids May. 07, 2019
-
Patent Title: Asymmetric auxiliary group Jan. 01, 2019
-
Patent Title: Chiral design Dec. 25, 2018
-
Patent Title: Chiral control May. 29, 2018
-
Patent Title: Chiral control Feb. 06, 2018
-
Patent Title: Nucleic acid prodrugs and methods of use thereof Aug. 29, 2017
-
Patent Title: Methods for the synthesis of functionalized nucleic acids Mar. 28, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of WVE in WallStreetBets Daily Discussion
Recent insights relating to WVE
Recent picks made for WVE stock on CNBC
ETFs with the largest estimated holdings in WVE
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view WVE Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.